MXPA02012944A - Analogos de acido graso para el tratamiento de cancer. - Google Patents

Analogos de acido graso para el tratamiento de cancer.

Info

Publication number
MXPA02012944A
MXPA02012944A MXPA02012944A MXPA02012944A MXPA02012944A MX PA02012944 A MXPA02012944 A MX PA02012944A MX PA02012944 A MXPA02012944 A MX PA02012944A MX PA02012944 A MXPA02012944 A MX PA02012944A MX PA02012944 A MXPA02012944 A MX PA02012944A
Authority
MX
Mexico
Prior art keywords
alkyl
treatment
fatty acid
acid analogues
cancer
Prior art date
Application number
MXPA02012944A
Other languages
English (en)
Inventor
Rolf Berge
Original Assignee
Thia Medica As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As filed Critical Thia Medica As
Publication of MXPA02012944A publication Critical patent/MXPA02012944A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere a analogos de acido graso de la formula general (I) : R1-[Xi-CH2]n-COOR2, en donde R1 es un alqueno de 1 a 24 atomos de carbono con uno o mas, dobles enlaces y/o con uno o mas triples enlaces; y/o un alquino de 1 a 24 atomos de carbono, y/o un alquilo de 1 a 24 atomos de carbono, o un alquilo sustituido en una o varias posiciones con uno o mas compuestos seleccionados del grupo que comprende fluoruro, cloruro, hidroxilo, alcoxi de 1 a 4 atomos de carbono, alquiltio de 1 a 4 atomos de carbono, aciloxi de 2 a 5 atomos de carbono, o alquilo de 1 a 4 atomos de carbono, y en donde R2 representa hidrogeno o alquilo de 1 a 4 atomos de carbono, y en donde n es un numero entero de 1 a 12, y en donde i es un numero impar e indica la posicion relativa a COOR2, y en donde Xi independiente uno de otro se seleccionan del grupo que comprende O, S, SO, SO2, Se y CH2, y con la condicion de que al menos uno de Xi no sea CH2, que pueden ser utilizados para el tratamiento y/o prevencion de neoplasmas metastaticos primarios y secundarios.
MXPA02012944A 2000-07-13 2001-07-13 Analogos de acido graso para el tratamiento de cancer. MXPA02012944A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20003591A NO20003591L (no) 2000-07-13 2000-07-13 Fettsyreanaloger for behandling av kreft
PCT/NO2001/000301 WO2002003983A1 (en) 2000-07-13 2001-07-13 Fatty acid analogues for the treatment of cancer

Publications (1)

Publication Number Publication Date
MXPA02012944A true MXPA02012944A (es) 2004-05-17

Family

ID=19911376

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012944A MXPA02012944A (es) 2000-07-13 2001-07-13 Analogos de acido graso para el tratamiento de cancer.

Country Status (18)

Country Link
US (1) US7378443B2 (es)
EP (1) EP1313463B1 (es)
JP (1) JP2004502732A (es)
KR (2) KR20080071598A (es)
CN (1) CN100569228C (es)
AT (1) ATE320802T1 (es)
AU (2) AU2001272860B2 (es)
BR (1) BR0112399A (es)
CA (1) CA2414480A1 (es)
DE (1) DE60118198T2 (es)
ES (1) ES2261441T3 (es)
HK (1) HK1057473A1 (es)
MX (1) MXPA02012944A (es)
NO (2) NO20003591L (es)
NZ (1) NZ523316A (es)
RU (1) RU2283105C2 (es)
WO (1) WO2002003983A1 (es)
ZA (1) ZA200210028B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO328803B1 (no) 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
JP5008258B2 (ja) 2002-06-20 2012-08-22 アイシー・ベック・リミテッド 含硫黄ホスホリピド誘導体
AU2005264781B2 (en) 2004-07-19 2011-07-28 Life Science Nutrition As Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
US8758323B2 (en) 2009-07-30 2014-06-24 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CA3052449C (en) 2013-03-11 2021-10-19 Jan Remmereit Lipid compositions comprising 5, 11, 14-eicosatrienoic acid and conjugated linoleic acids
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
DE102014116958B9 (de) * 2014-11-19 2017-10-05 Trumpf Laser- Und Systemtechnik Gmbh Optisches System zur Strahlformung eines Laserstrahls, Laserbearbeitungsanlage, Verfahren zur Materialbearbeitung und Verwenden einer gemeinsamen langgezogenen Fokuszone zur Lasermaterialbearbeitung
CA2989157A1 (en) * 2015-06-11 2016-12-15 University Of Miami Cancer treatment and diagnosis
CN105498622B (zh) * 2015-12-10 2017-10-17 江南大学 一种含硒表面活性剂及其制备方法和应用
CN107235880B (zh) * 2017-06-30 2018-10-30 江南大学 一种含硒阳离子表面活性剂及其应用
GB201910644D0 (en) * 2019-07-25 2019-09-11 Coegin Pharma As Cancer Treatment
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
CN115260964A (zh) * 2022-08-29 2022-11-01 烟台市福山义昌精细化工厂 一种石油油管丝扣专用密封胶及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0686377B2 (ja) * 1985-09-30 1994-11-02 日清製粉株式会社 がん転移抑制剤
JPH0797320A (ja) * 1993-08-04 1995-04-11 Takuma Sasaki 制癌剤
US6358915B1 (en) * 1995-03-07 2002-03-19 George Washington University Methods for inhibiting metastasis
EP0768084B1 (en) * 1995-04-10 2002-09-11 Taiho Pharmaceutical Co., Ltd. Cancerous metastasis inhibitor
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
JP4993878B2 (ja) * 2005-06-28 2012-08-08 ダイキョーニシカワ株式会社 多気筒エンジンの吸気装置

Also Published As

Publication number Publication date
KR20030016399A (ko) 2003-02-26
BR0112399A (pt) 2003-05-27
NO324634B1 (no) 2007-11-26
AU2001272860B2 (en) 2005-11-24
KR20080071598A (ko) 2008-08-04
CN1441671A (zh) 2003-09-10
HK1057473A1 (en) 2004-04-08
EP1313463B1 (en) 2006-03-22
WO2002003983A1 (en) 2002-01-17
US7378443B2 (en) 2008-05-27
AU7286001A (en) 2002-01-21
EP1313463A1 (en) 2003-05-28
KR100861428B1 (ko) 2008-10-02
NZ523316A (en) 2004-09-24
JP2004502732A (ja) 2004-01-29
NO20025930L (no) 2003-01-13
DE60118198D1 (de) 2006-05-11
NO20003591L (no) 2002-01-14
CA2414480A1 (en) 2002-01-17
US20040024063A1 (en) 2004-02-05
RU2283105C2 (ru) 2006-09-10
ES2261441T3 (es) 2006-11-16
ATE320802T1 (de) 2006-04-15
ZA200210028B (en) 2004-01-26
DE60118198T2 (de) 2007-01-25
CN100569228C (zh) 2009-12-16
NO20003591D0 (no) 2000-07-13
NO20025930D0 (no) 2002-12-11

Similar Documents

Publication Publication Date Title
MXPA02012944A (es) Analogos de acido graso para el tratamiento de cancer.
HK1034911A1 (en) Novel fatty acid analogues for the treatment of secondary restenosis
PH12012501351A1 (en) Synthesis of eporthilones, intermediates thereto, analogues and uses thereof
ES2193874A1 (es) Compuestos naturales y derivados de estos para la prevencion y el tratamiento de enfermedades cardiovasculares, hepaticas, renales y cosmeticas.
MXPA04006542A (es) Composiciones bucales estables que contienen complejos de fosfopeptido de caseina y fluooruro.
MY133299A (en) Skin moisturizing composition comprising a choline salt
AU9441901A (en) Fatty acid analogues for the treatment of proliferative skin disorders
MXPA04006541A (es) Composiciones bucales estables que contienen complejos de fosfopeptido de caseina y fluoruro.
KR970074763A (ko) 불소화된 비타민 d₃ 유사체
DE69814109D1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
BR0108950A (pt) Novos análogos de ácido graxo
IL146190A0 (en) Dermal anesthetic agents
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
MXPA03004427A (es) Analogos de acido graso para el tratamiento de desordenes inflamatorios y autoinmunes.
DK1250337T3 (da) Substituerede homopiperidinylbenzimidazol-analoger som fundus-relaksanter
TR200504091T2 (tr) (7alfa,17alfa)-17-hidroksi-7-metil-19-nor-17-pregn-5(10)-en 20-in-3-on içeren yüksek saflıkta bileşim.
GB0005743D0 (en) Pharmaceutical compositions including alginates
TR200100070A2 (tr) Bileşim
PT1651596E (pt) Novos derivados de 4,4?-ditiobis-(3-aminobutano-1-sulfonatos) e composições que os contêm
TW200504048A (en) Cyclic onium compounds and glucosidase inhibitors
CL2004000579A1 (es) Uso de dienogest para preparar composiciones farmaceuticas destinadas a reducir el cuerpo de la glandula mamaria.
BR9809661A (pt) Redução de halogenetos aromáticos
MY130184A (en) Dermal anesthetic agents

Legal Events

Date Code Title Description
FG Grant or registration